Unfractionated or low molecular weight heparin for induction of remission in ulcerative colitis: A cochrane inflammatory bowel disease and functional bowel disorders systematic review of randomized trials

Inflammatory Bowel Diseases

Volumn 17, Issue 9, 2011, Pages 1979-1986

  Chande, Nilesh ^a   MacDonald, John K ^b   Wang, Josh J ^c   McDonald, John W D ^b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

^c WESTERN UNIVERSITY   (Canada)

Author keywords

heparin; inflammatory bowel disease; low molecular weight heparin; ulcerative colitis

Indexed keywords

AMINOSALICYLIC ACID; ENOXAPARIN; HEPARIN; METHYLPREDNISOLONE; PARNAPARIN; PLACEBO; PREDNISOLONE; REVIPARIN; STEROID; TINZAPARIN;

DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; ENDOSCOPY; HISTOLOGY; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM HEMORRHAGE; REMISSION; REVIEW; SYSTEMATIC REVIEW; TREATMENT RESPONSE; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

ANTICOAGULANTS; COLITIS, ULCERATIVE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INFLAMMATORY BOWEL DISEASES; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION;

EID: 80955177515     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21776     Document Type: Review

References (50)

1. Sutherland L, MacDonald JK,. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006: CD000543.
2. Sutherland L, MacDonald JK,. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006: CD000544.
3. Timmer A, McDonald JW, MacDonald JK,. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2007: CD000478.
4. Ardizzone S, Maconi G, Russo A, et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut. 2006; 55: 47-53. (Pubitemid 41820634)
5. Hawthorne AB, Logan RF, Hawkey CJ, et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ. 1992; 305: 20-22.
6. Jewell DP, Truelove SC,. Azathioprine in ulcerative colitis: final report on controlled therapeutic trial. Br Med J. 1974; 4: 627-630.
7. Lawson MM, Thomas AG, Akobeng AK,. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006: CD005112.
8. Rutgeerts P, Sandborn B, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353: 2462-2476. (Pubitemid 41770166)
9. Shibolet O, Regushevskaya E, Brezis M, et al. Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database Syst Rev. 2005: CD004277.
10. Bernstein CN, Blanchard JF, Houston DS, et al. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb Haemost. 2001; 85: 430-434. (Pubitemid 32233013)
11. Hudson M, Chitolie A, Hutton RA, et al. Thrombotic vascular risk factors in inflammatory bowel disease. Gut. 1996; 38: 733-737. (Pubitemid 26167482)
12. Souto JC, Martinez E, Roca M, et al. Prothrombotic state and signs of endothelial lesion in plasma of patients with inflammatory bowel disease. Dig Dis Sci. 1995; 40: 1883-1889.
13. Dhillon AP, Anthony A, Sim R, et al. Mucosal capillary thrombi in rectal biopsies. Histopathology. 1992; 21: 127-133.
14. Zavgorodnii LG, Mustiats AP,. Use of anticoagulants in the combined treatment of nonspecific ulcerative colitis [Primenenie antikoaguliantov v kompleksnom lechenii nespetsificheskogo iazvennogo kolita.] Klin Med (Mosk). 1982; 60: 74-80.
15. Chande N, McDonald JW, MacDonald JK, et al. Unfractionated or low-molecular weight heparin for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2001: CD006774.
16. Higgins JPT, Altman DG, (eds.). Chapter 8: Assessing risk of bias in included studies. In:, Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008. Available from:.
17. Bloom S, Kiilerich S, Lassen MR, et al. Low molecular weight heparin (tinzaparin) vs. placebo in the treatment of mild to moderately active ulcerative colitis. Aliment Pharmacol Ther. 2004; 19: 871-878. (Pubitemid 38534816)
18. Celasco G, Papa A, Jones R, et al. Clinical trial: oral colon-release parnaparin sodium tablets (CD-01-05 MMX) for active left-sided ulcerative colitis. Aliment Pharmacol Ther. 2010; 31: 375-386.
19. de Bievre MA, Vrij AA, Schoon EJ, et al. Randomized, placebo-controlled trial of low molecular weight heparin in active ulcerative colitis. Inflamm Bowel Dis. 2007; 13: 753-758. (Pubitemid 46909991)
20. Zezos P, Papaioannou G, Nikolaidis N, et al. Low-molecular-weight heparin (enoxaparin) as adjuvant therapy in the treatment of active ulcerative colitis: a randomized, controlled, comparative study. Aliment Pharmacol Ther. 2006; 23: 1443-1453.
21. Panes J, Esteve M, Cabre E, et al. Comparison of heparin and steroids in the treatment of moderate and severe ulcerative colitis. Gastroenterology. 2000; 119: 903-908.
22. Korzenik JR, Robert ME, Bitton A, et al. A multicenter, randomized, controlled trial of heparin for the treatment of ulcerative colitis. Gastroenterology. 1999; 116: A752.
23. Korzenik J, Miner P, Stanton D, et al. Multicenter, randomized, double-blind, placebo-controlled trial of deligoparin (ultra low molecular weight heparin) for active ulcerative colitis. Gastroenterology. 2003; 124 (4 suppl 1): A67.
24. Torkvist L, Stahlberg D, Bohman L, et al. LMWH for the treatment of mild to moderately active steroid refractory/dependent UC-An independent, multicenter, randomised, controlled study. Gastroenterology. 2001; 120 (5 suppl 1): A277.
25. Ang YS, Mahmud N, White B, et al. Randomized comparison of unfractionated heparin with corticosteroids in severe active inflammatory bowel disease. Aliment Pharmacol Ther. 2000; 14: 1015-1022. (Pubitemid 30618162)
26. Gaffney PR, O'Leary JJ, Doyle CT, et al. Response to heparin in patients with ulcerative colitis. Lancet. 1991; 337: 238-239.
27. Gaffney PR, Doyle CT, Gaffney A, et al. Paradoxical response to heparin in 10 patients with ulcerative colitis. Am J Gastroenterol. 1995; 90: 220-223.
28. Miyake Y, Suwaki K, Fujimoto T, et al. Two cases of intractable ulcerative colitis with successful heparin treatment. Nippon Shokakibyo Gakkai Zasshi. 1998; 95: 1027-1031. (Pubitemid 28440542)
29. Zhernakova TV, Kashmenskaia NA, Mal'tseva IV, et al. Hemostasis and heparin therapy in nonspecific ulcerative colitis. Sov Med. 1984: 110-113.
30. Thorsteinsson GS, Magnussson M, Hallberg LM, et al. Cerebral venous thrombosis and heparin-induced thrombocytopenia in an 18-year old male with severe ulcerative colitis. World J Gastroenterol. 2008; 14: 4576-4579.
31. Ikehata A, Yamakawa M, Kitagawa M, et al. A case of refractory ulcerative colitis treated successfully with a combination of low-dose heparin and 5-aminosalicylic acid. Nippon Shokakibyo Gakkai Zasshi. 2003; 100: 567-571. (Pubitemid 36702224)
32. Matsuzaki T, Nakazawa T, Nakazawa A, et al. A case of ulcerative colitis (proctitis type) complicated with deep venous thrombosis and treated with heparin successfully. Nippon Shokakibyo Gakkai Zasshi. 2001; 98: 300-306. (Pubitemid 32231349)
33. Ashizuka S, Nishiura R, Ishikawa N, et al. Leukocytapheresis for ulcerative colitis: a comparative study of anticoagulant (nafamostat mesilate vs. dalteparin sodium) for reducing clinical complications. Ther Apher Dial. 2006; 10: 54-58.
34. Brazier F, Yzet T, Boruchowicz A, et al. Treatment of ulcerative colitis with heparin. Gastroenterology. 1996; 110 (suppl): A782.
35. Cui HF, Jiang XL,. Treatment of corticosteroid-resistant ulcerative colitis with oral low molecular weight heparin. World J Gastroenterol. 1999; 5: 448-450.
36. Dotan I, Hallak A, Arber N, et al. Low-dose low-molecular weight heparin (enoxaparin) is effective as adjuvant treatment in active ulcerative colitis: an open trial. Dig Dis Sci. 2001; 46: 2239-2244. (Pubitemid 32955238)
37. Evans RC, Wong VS, Morris AI, et al. Treatment of corticosteroid- resistant ulcerative colitis with heparin-a report of 16 cases. Aliment Pharmacol Ther. 1997; 11: 1037-1040.
38. Folwaczny C, Fricke H, Spannagl M, et al. Heparin for therapy of ulcerative colitis: therapy of a concomitant phenomenon or indication of pathophysiology? Z Gastroenterol. 1995; 33: 723-724.
39. Folwaczny C, Fricke H, Endres S, et al. Anti-inflammatory properties of unfractioned heparin in patients with highly active ulcerative colitis: a pilot study. Am J Gastroenterol. 1997; 92: 911-912. (Pubitemid 27200828)
40. Folwaczny C, Wiebecke B, Loeschke K,. Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease. Am J Gastroenterol. 1999; 94: 1551-1555. (Pubitemid 29260445)
41. Pastorelli L, Saibeni S, Spina L, et al. Oral, colonic-release low-molecular-weight heparin: an initial open study of Parnaparin-MMX for the treatment of mild-to-moderate left-sided ulcerative colitis. Aliment Pharmacol Ther. 2008; 28: 581-588.
42. Saibeni S, Spina L, Signorelli C, et al. Safety and efficacy of oral, colonic-release, low molecular weight heparin-MMX for the treatment of mild to moderate left-sided ulcerative colitis: preliminary report of a pilot study. Gastroenterology. 2006; 130 (4 suppl 2): A662.
43. Torkvist L, Thorlacius H, Lapidus A, et al. Low molecular weight heparin as adjuvant therapy in ulcerative colitis. Gastroenterology. 1998; 114: A1112-1113.
44. Torkvist L, Thorlacius H, Sjoqvist U, et al. Low molecular weight heparin as adjuvant therapy in active ulcerative colitis. Aliment Pharmacol Ther. 1999; 13: 1323-1328. (Pubitemid 29462307)
45. Vrij AA, Jansen JM, Schoon EJ, et al. Low molecular weight heparin treatment in steroid refractory ulcerative colitis: clinical outcome and influence on mucosal capillary thrombi. Scand J Gastroenterol Suppl. 2001: 41-47. (Pubitemid 33070910)
46. Rachmilewitz D,. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomized trial. BMJ. 1989; 296: 82-86. (Pubitemid 19032930)
47. Vrij AA, Oberndorff-Klein-Woolthuis AH, Dijkstra G, et al. Thrombin generation in mesalazine refractory ulcerative colitis and the influence of low molecular weight heparin. J Thromb Thrombolysis. 2007; 24: 175-182.
48. Lever R, Page CP,. Novel drug development opportunities for heparin. Nat Rev Drug Discov. 2002; 1: 140.
49. Bhandari M, Busse JW, Jackowski D, et al. Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. CMAJ. 2004; 170: 477-480. (Pubitemid 38293642)
50. Lexchin J, Bero LA, Djulbegovic B, et al. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003; 326: 1167-1170. (Pubitemid 36649048)